Apr 30, 2026 04:05PM Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner

Mar 27, 2026 08:02AM Shuttle Pharmaceuticals launches AI agent for drug discovery workflows

Mar 27, 2026 08:00AM RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Mar 26, 2026 04:07PM Shuttle Pharmaceuticals updates molecule.ai platform with AI reasoning

Mar 26, 2026 04:05PM Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Mar 6, 2026 08:02AM Shuttle Pharmaceuticals announces $3.5 million public offering

Mar 6, 2026 08:00AM Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Feb 11, 2026 06:06AM Shuttle Pharmaceuticals (SHPH) files for 2.23M share offering

Jan 13, 2026 04:00PM Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

Nov 21, 2025 09:33AM Shuttle Pharmaceuticals acquires AI drug discovery firm for $8 million

Nov 21, 2025 09:30AM Shuttle Pharmaceuticals Acquires AI Health Platform

Nov 18, 2025 05:02PM Shuttle Pharmaceuticals (SHPH) files for 625K share offering by selling stockholders

Nov 3, 2025 07:02AM Shuttle Pharmaceuticals raises $2.5 million in private placement

Nov 3, 2025 07:00AM Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Oct 22, 2025 10:00AM Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Oct 22, 2025 07:00AM Shuttle Pharmaceuticals signs LOI to acquire Molecule.AI for $10 million

Oct 22, 2025 07:00AM Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Oct 21, 2025 05:55PM Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Oct 21, 2025 04:07PM Shuttle Pharmaceuticals enters $10 million acquisition deal for AI platform

Oct 21, 2025 04:05PM Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Oct 10, 2025 10:20AM Shuttle Pharmaceuticals signs $10 million acquisition deal for AI drug platform

Oct 9, 2025 04:16PM Shuttle Pharmaceuticals signs letter of intent to acquire Molecule.ai for $10M

Aug 5, 2025 06:06AM Shuttle Pharmaceuticals (SHPH) Files for 1.18M Share Offering by Selling Stockholders

Jun 20, 2025 03:56PM Shuttle Pharmaceuticals (SHPH) Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Jun 12, 2025 08:31AM Shuttle Pharmaceuticals (SHPH) Announces Proposed 1:25 Reverse Share Split

Jun 4, 2025 04:01PM Shuttle Pharmaceuticals (SHPH) Appoints George Scorsis as Board Chair

May 8, 2025 04:04PM Shuttle Pharmaceuticals (SHPH) FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Apr 10, 2025 04:02PM Shuttle Pharmaceuticals (SHPH) files provisional patent for PSMA Ligand Conjugates

Mar 12, 2025 09:25AM Shuttle Pharmaceuticals (SHPH) Prices 19.17M Share Offering at $0.30/sh

Mar 12, 2025 06:20AM Shuttle Pharmaceuticals (SHPH) Appoints Christopher Cooper as Interim Co-CEO

Feb 26, 2025 10:45AM Shuttle Pharmaceuticals (SHPH) Provides Corporate Update and Reports 2024 Results

Jan 21, 2025 09:01AM Shuttle Pharmaceuticals (SHPH) Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 30, 2024 06:06AM Shuttle Pharmaceuticals (SHPH) Prices 2.95M Share and Warrant Offering at $1.525/sh

Oct 18, 2024 09:10AM Shuttle Pharmaceuticals (SHPH) Files for 7.21M Share and Warrant Offering

Sep 20, 2024 06:11AM Shuttle Pharmaceuticals (SHPH) Files for Share and Warrant Offering

Sep 16, 2024 09:01AM Shuttle Pharmaceuticals (SHPH) Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 11, 2024 01:00PM Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Sep 11, 2024 01:00PM Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Sep 5, 2024 09:02AM Shuttle Pharmaceuticals (SHPH) Issues US Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

Aug 28, 2024 09:00AM Shuttle Pharmaceuticals (SHPH) Regains Nasdaq Compliance

Jul 19, 2024 09:01AM Shuttle Pharma's (SHPH) Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of ER + BC Cells, as Reported in PLOS ONE

Jun 18, 2024 09:01AM Shuttle Pharmaceuticals (SHPH) Appoints Timothy Lorber as Chief Financial Officer